casno. : CAS 595-33-5
Megestrol belongs to 17 α- Hydroxyprogesterone derivatives are highly effective synthetic progesterone. Their progesterone effect is about 75 times that of progesterone when taken orally and 50 times that of progesterone when injected. This product has obvious anti estrogen effect, no estrogen or androgen activity, and no protein assimilation effect. It can inhibit the release of hypothalamic gonadotropin releasing hormone (GnRH), and act on the adenohypophysis to reduce its sensitivity to GnRH, thus blocking the release of pituitary gonadotropin and producing significant ovulation inhibition, so it can be used together with ethinylestradiol as a short-term contraceptive. When used alone in large doses, this product can also make cervical mucus viscous, which is not conducive to the passage of sperm, inhibit the normal development of endometrial glands, and prevent the implantation of fertilized eggs.
In addition, this product has a certain inhibitory effect on hormone dependent tumors. Its mechanism may be to control the development and growth of ovarian follicles by affecting the secretion of pituitary gonadotropin (FSH), thereby reducing the production of estrogen; In addition, it can also act on estrogen receptor, interfere with its binding with estrogen, and inhibit the growth of tumor cells.